{
    "clinical_study": {
        "@rank": "112774", 
        "acronym": "LZDPPT6", 
        "arm_group": [
            {
                "arm_group_label": "Administration of linezolid to 6 healthy volunteers", 
                "arm_group_type": "Other", 
                "description": "Administration of linezolid to 6 healthy volunteers {six healthy subjects with normal renal function (CLcr \u02c380 ml/min)}"
            }, 
            {
                "arm_group_label": "Administration of linezolid to 6 acute renal failure patients", 
                "arm_group_type": "Other", 
                "description": "Administration of linezolid to 6 acute renal failure patients {(six patients with acute renal failure (RF) (30\u02c2CLcr\u02c280 ml/mine)}"
            }, 
            {
                "arm_group_label": "Administration of linezolid to 6 ESRD patients", 
                "arm_group_type": "Other", 
                "description": "Administration of linezolid to 6 end-stage renal disease (ESRD) patients during an intra-dialytic period (on-dialysis): 6 patients on long term HD (minimum period of dialysis was 40 month while maximum period were 130 month) with an ideal body weight of >60 kg (calculated as {height (cm) -100}\u00d70.9) and a body mass index between 20 and 26 kg/m2 (calculated as {weight (kg)/height (m2)})."
            }
        ], 
        "brief_summary": {
            "textblock": "Renal failure patients were treated with linezolid (LZD) for proven or suspected infections\n      by multiresistant Gram-positive cocci. The aim of this study is to determine if dose\n      adjustment of LZD is needed as a function of renal impairment or not, especially that a\n      significant component of LZD is eliminated unchanged in urine."
        }, 
        "brief_title": "Linezolid Pharmacokinetics In Patients With Impaired Renal Function (PPT6)", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Renal Failure", 
            "Impaired Renal Function"
        ], 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy subjects with normal renal function (CLcr \u02c380 ml/min);\n\n          -  Patients with acute renal failure (RF) (30\u02c2CLcr\u02c280 ml/mine)\n\n          -  Patients on long term HD with an ideal body weight of >60 kg and a body mass index\n             between 20 and 26 kg/m2\n\n          -  Passed all the screening parameters\n\n          -  Free of any drug exposure known to interfere with the pharmacokinetics or assay of\n             linezolid for at least 10 days prior to the study\n\n          -  Able to communicate effectively with study personnel, be literate, and able to give\n             consent.\n\n        Exclusion Criteria:\n\n        Had a history of clinically significant organ dysfunction other than renal disease or\n        those diseases associated with renal disease (as in case of acute RF or ESRD patients) Had\n        physical examination or laboratory test results outside the inclusion such as; sitting\n        systolic BP (SBP) of >140 or <100 mmHg, diastolic BP (DBP) > 90 or <60mm Hg (as in case of\n        healthy volunteers and acute RF patients), or a pulse rate of > 95 or < 50 beats/min at\n        screening; history of orthostatic hypotension; history of serious intolerance, allergy or\n        sensitivity to linezolid ; history of blood dyscrasias; history of alcohol, smoking, or\n        drug abuse; donation of blood during the 8 weeks prior to the study or plans to donate\n        blood during or within 8 weeks of completing the study; unable to tolerate vein puncture\n        and multiple blood samplings; any surgical/medical condition that might alter the\n        absorption, distribution, metabolism, excretion of linezolid ; or can't follow\n        instructions, according to the investigator's opinion.\n\n        -"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "22 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087566", 
            "org_study_id": "LZDPPT6"
        }, 
        "intervention": {
            "arm_group_label": [
                "Administration of linezolid to 6 healthy volunteers", 
                "Administration of linezolid to 6 acute renal failure patients", 
                "Administration of linezolid to 6 ESRD patients"
            ], 
            "intervention_name": "600 mg linezolid", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Linezolid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Linezolid", 
            "Pharmacokinetics", 
            "Haemodialysis", 
            "Dosing adjustment", 
            "Eligible subjects were classified into three groups depending on their 24-h urinary creatinine clearance (CLcr) values or HD status.", 
            "Group 1, included 6 healthy subjects with normal renal function (CLcr \u02c380 ml/min);", 
            "Group 2, included 6 patients with acute renal failure (RF) (30\u02c2CLcr\u02c280 ml/mine);", 
            "Group 3, included 6 patients on long term haemodialysis  (minimum period of dialysis was 40 month while maximum period were 130 month)"
        ], 
        "lastchanged_date": "March 13, 2014", 
        "number_of_arms": "3", 
        "official_title": "Single-Dose Linezolid Pharmacokinetics In Critically Ill Patients With Impaired Renal Function Especially Chronic Haemodialysis Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Egypt: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Tolerability was assessed based on changes in vital signs (temperature, blood pressure, pulse, and heart rate), measured before dosing in each period and approximately every 4 hours thereafter, and laboratory tests (hematology, biochemistry, liver function, and urinalysis), and performed at baseline and at the end of the study. In addition, a physician questioned volunteers about any adverse events occurring during the study, addressed them as necessary, and recorded them on the appropriate form. This physician was not blinded to treatment, but had no involvement in the study.", 
            "measure": "Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for the duration of study, an expected average of 6 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087566"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Damanhour University", 
            "investigator_full_name": "Sally Helmy, PhD, CPHQ", 
            "investigator_title": "Faculty of Pharmacy-Damanhour University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Damanhour University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Damanhour University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}